Class: Medium chain triglycerides
- Powder for oral solution 40 g (20 g of medium-chain triglycerides [MCTs])
Induces hyperketonemia and provides an alternative energy substrate to glucose in the brains of patients with Alzheimer disease.
After oral administration, caprylidene is processed by lipase in the gut, and the resulting medium-chain fatty acids are absorbed into the portal vein.
The ketone body beta-hydroxybutyrate crosses the blood-brain barrier and is then taken up by neurons.
The medium-chain fatty acids rapidly pass directly to the liver, where they undergo obligate oxidation.
Special PopulationsRenal Function Impairment
No clinical studies have been performed in patients with renal insufficiency.Hepatic Function Impairment
No clinical studies have been performed in patients with hepatic insufficiency.Children
No clinical studies have been performed in children.Gender
No significant findings were associated with patient's response by sex.Race
No significant findings were associated with patient's response by race or ethnicity.
Indications and Usage
For the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer disease.
Allergy to milk or soy.
Dosage and AdministrationAdults
PO 40 g/day (1 packet of caprylidene powder, containing 20 g of MCTs) taken during breakfast.
- The contents of each packet should be added to 4 to 8 oz (118 to 236 mL) of water, as preferred, shaken until fully blended, and consumed immediately.
- Administer orally once a day during breakfast.
- Caprylidene is a medical food containing a proprietary formulation of MCTs, specifically caprylic triglyceride.
Store at 59° to 86°F, sealed and protected from light and moisture.
None well documented.
Dizziness (7%); headache (6%); fatigue (4%).
Diarrhea (24%); nausea (20%); abdominal distension, flatulence (17%); dyspepsia (9%); abdominal pain (5%).
Urinary tract infection (5%).
Cough, rhinitis (4%).
Periodically monitor triglycerides in patients who meet the criteria indicative of metabolic syndrome.
No clinical studies have been performed in children.
Contains palm or coconut oil, caseinate (milk-derived protein), whey (milk), and lecithin (soy). Do not administer to patients with known allergies to these components.
Observed in patients with probable metabolic syndrome.
Use with caution in patients with a history of GI inflammatory conditions, such as irritable bowel syndrome, diverticular disease, chronic gastritis, and severe gastroesophageal reflux disease.
Use with caution in patients at risk for ketoacidosis (eg, alcoholism, poorly controlled diabetes).
Mild increases in BUN, uric acid, or creatinine were observed.
- Advise patients that caprylidene is a medical food product distributed by prescription and must be administered under the supervision of a health care provider.
- Counsel patients that mild GI symptoms (eg, diarrhea, dyspepsia, flatulence, unsettled stomach) may occur. Medications such as simethicone, antacids, and antidiarrheals may be useful.
- Inform patients to take caprylidene with food.
Copyright © 2009 Wolters Kluwer Health.